Cue Biopharma Inc Prix / Ventes
Quel est le Prix / Ventes de Cue Biopharma Inc?
Le Prix / Ventes de Cue Biopharma Inc est 15.31
Quelle est la définition de Prix / Ventes?
Le rapport prix / ventes est le prix des actions d'une entreprise par rapport à ses revenus.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Prix / Ventes des entreprises dans Health Care secteur sur NASDAQ par rapport à Cue Biopharma Inc
Que fait Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Entreprises avec prix / ventes similaire à Cue Biopharma Inc
- Dalal Street Investments a Prix / Ventes de 15.24
- MFA Inc a Prix / Ventes de 15.27
- APN Property a Prix / Ventes de 15.28
- P10 a Prix / Ventes de 15.28
- MPH Health Care AG a Prix / Ventes de 15.29
- Hermès International SCA a Prix / Ventes de 15.30
- Cue Biopharma Inc a Prix / Ventes de 15.31
- Maui Land & Pineapple Co a Prix / Ventes de 15.31
- Dunedin Income Growth Investment Trust Plc a Prix / Ventes de 15.32
- Lattice Semiconductor a Prix / Ventes de 15.32
- Mersana Therapeutics Inc a Prix / Ventes de 15.33
- Starwood European Real Estate Finance a Prix / Ventes de 15.33
- Wolfspeed Dl ,00125 a Prix / Ventes de 15.34